PET makes the move to everyday
By: Jane Lowers, Supplements editor
With CMS approval of FDG-PET for diagnosis and staging of lung, colon, and
selected other cancers, many early adopters of PET have their hands full. On the
horizon, however, are more advanced uses for PET that could entrench the
modality in the diagnosis and therapy of everything from neurodegenerative
disease to breast cancer.
This supplement to Diagnostic Imaging looks at PET's status from both sides:
the clinical advances that move beyond standard FDG applications and the
economic factors that PET facilities must consider when building their practice
around a new PET or PET/CT fusion scanner.
Dr. Harry Agress discusses the mechanics of opening and running a PET center
from hospital administrator buy-in to patient flow and generation of referrals.
A number of new users of PET/CT fusion equipment discuss the economic
practicalities of incorporating the new technology into an existing practice.
While the workload of both types of scanners is built around FDG, imagers may
need to expand their repertoire soon: As reports on breast cancer and
Alzheimer's disease imaging indicate, new tracers may soon blur the line between
imaging and treatment.